AbbVie	ABT-639
Mechanism of Action	Calcium channel, voltage-gated (Cav3.2, T-type) blocker http://iuphar-db.org/DATABASE/ObjectDisplayForward?objectId=536&familyId=80 http://www.ncbi.nlm.nih.gov/gene/8912
Overview	ABT-639 is a selective voltage-dependent T-type calcium channel blocker that has little or no activity at other calcium channels, including N-, L-, or P/Q types. Following oral administration, ABT-639 dose dependently reduced nociception in animal models of chronic joint and neuropathic pain.
Safety/Tolerability	Six-week studies have been conducted in rats and dogs in addition to a 13-week study in rats. Based on the evaluation of exposures at the no-observed-adverse-effect levels obtained from toxicology studies, there are sufficient safety margins maintained relative to exposures associated with the highest dose intended in clinical studies with regard to these preclinical findings.
Additional Information	ABT-639 has a favorable safety/tolerability profile in young and elderly healthy subjects. Dose escalation was only limited by preclinical safety margins – no MTD established. The PK profile for ABT-639 indicates ~ dose linearity in targeted dose range and supports BID dosing.
Suitable for and Exclusions	Suitable for dosing up to 6 weeks based on currently available safety data. Suitable for proposals for chemotherapy induced peripheral pain (CIPN) and other disease proposals. Proposals for use in diabetic neuropathic pain are not of interest.
Clinical Trials	http://clinicaltrials.gov/ct2/results?term=ABT639
Publications	None